These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35266259)

  • 1. Vitiligo worsened following the second dose of mRNA SARS-CoV-2 vaccine.
    Caroppo F; Deotto ML; Tartaglia J; Belloni Fortina A
    Dermatol Ther; 2022 Jun; 35(6):e15434. PubMed ID: 35266259
    [No Abstract]   [Full Text] [Related]  

  • 2. Worsening of the vitiligo following the second dose of the BNT162B2 mRNA COVID-19 vaccine.
    Okan G; Vural P
    Dermatol Ther; 2022 Mar; 35(3):e15280. PubMed ID: 34931408
    [No Abstract]   [Full Text] [Related]  

  • 3. Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine.
    Wang M; Wen W; Zhou M; Wang C; Feng ZH
    Am J Cardiol; 2022 Mar; 167():155-157. PubMed ID: 35063268
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1?
    Vuilleumier N; Pagano S; Ludewig B; Schmiedeberg K; Haller C; von Kempis J; Rubbert-Roth A
    Eur J Clin Invest; 2022 Feb; 52(2):e13713. PubMed ID: 34841527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to Comment on D'Addio et al. Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccines in a Cohort of Patients With Type 1 Diabetes. Diabetes 2022;71:1800-1806.
    D'Addio F; Fiorina P
    Diabetes; 2022 Sep; 71(9):e14. PubMed ID: 35984961
    [No Abstract]   [Full Text] [Related]  

  • 6. Various aspects of the relationship between vitiligo and the COVID-19 pandemic or SARS-CoV-2 vaccines: Clinical pearls for dermatologists.
    Aryanian Z; Balighi K; Hatami P; Goodarzi A; Janbakhsh A; Afshar ZM
    J Cosmet Dermatol; 2023 Apr; 22(4):1152-1156. PubMed ID: 36762373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccine-associated vitiligo: A cross-sectional study in a tertiary referral center and systematic review.
    Tsai TF; Ng CY
    J Dermatol; 2023 Aug; 50(8):982-989. PubMed ID: 37186102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urticaria 12 Days After COVID-19 mRNA Booster Vaccination.
    Wolfson AR; Freeman EE; Blumenthal KG
    JAMA; 2022 May; 327(17):1702-1703. PubMed ID: 35420647
    [No Abstract]   [Full Text] [Related]  

  • 9. Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection.
    Stellini R; Gianello R; Meloni A; Croce E; Materzanini P; Gomarasca W
    Infection; 2022 Jun; 50(3):791-793. PubMed ID: 34855188
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients.
    Bloomfield M; Parackova Z; Hanzlikova J; Lastovicka J; Sediva A
    J Clin Immunol; 2022 Feb; 42(2):266-269. PubMed ID: 34718945
    [No Abstract]   [Full Text] [Related]  

  • 11. T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine.
    Atanackovic D; Kreitman RJ; Cohen J; Hardy NM; Omili D; Iraguha T; Burbelo PD; Gebru E; Fan X; Baddley J; Luetkens T; Dahiya S; Rapoport AP
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urticarial vasculitis triggered by SARS-CoV-2 vaccine (mRNA vaccine).
    Daldoul M; Korbi M; Bellalah A; Ben Fadhel N; Belhadjali H; Zili J
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):e743-e744. PubMed ID: 35604050
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
    Chanut M; Jaidi R; Kohn M; Grange T; Brones C; Lombion N; Rousselot P; Longval T
    Platelets; 2022 May; 33(4):652-653. PubMed ID: 35225144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over.
    Alicandro G; Daccó V; Cariani L; Contarini M; Morlacchi LC; Rosazza C; Sciarrabba CS; Ferraro F; Lanfranchi C; Orena BS; Gramegna A; Blasi F; Colombo C
    J Cyst Fibros; 2022 May; 21(3):e173-e175. PubMed ID: 35256306
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
    Greenberg RS; Ruddy JA; Boyarsky BJ; Werbel WA; Garonzik-Wang JM; Segev DL; Imus PH
    BMC Cancer; 2021 Dec; 21(1):1354. PubMed ID: 34961488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine.
    Zeng G
    Lancet Microbe; 2022 Aug; 3(8):e561. PubMed ID: 35659883
    [No Abstract]   [Full Text] [Related]  

  • 17. A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients.
    Masset C; Benotmane I; Dantal J; Garandeau C; Gauthier-Vargas G; Cantarovich D; Meurette A; Giral M; Caillard S; Blancho G
    Kidney Int; 2022 Apr; 101(4):825-826. PubMed ID: 35167873
    [No Abstract]   [Full Text] [Related]  

  • 18. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study.
    Haslak F; Gunalp A; Cebi MN; Yildiz M; Adrovic A; Sahin S; Barut K; Kasapcopur O
    Int J Rheum Dis; 2022 Mar; 25(3):353-363. PubMed ID: 34978376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newly-developed vitiligo following COVID-19 mRNA vaccine.
    Uğurer E; Sivaz O; Kıvanç Altunay İ
    J Cosmet Dermatol; 2022 Apr; 21(4):1350-1351. PubMed ID: 35152540
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.